The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Guest Editorial

My introduction to, and lessons learned from, Rick Pazdur

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

This editorial has been adapted from “Drugs and the FDA: Safety, Efficacy, and the Public’s Trust.”

Rick Pazdur, MD, the newly appointed director for the Center for Drug Evaluation and Research at the FDA, has been described as “greyhound thin” as a result of his dedication to cycling and lifting weights in the gym each day and, for a long time, a vegetarian diet. I first met him when he was the director of the Office of Oncology Drug Products (ODP) within CDER, in 2009. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Mikkael A. Sekeres, MD, MS
Chief, Division of Hematology, Professor of medicine, Sylvester Comprehensive Cancer Center, University of Miami; Author, “Drugs and the FDA: Safety, Efficacy, and the Public’s Trust”
Table of Contents

YOU MAY BE INTERESTED IN

Regulatory News

Hegseth orders testosterone testing for troops as FDA moves to loosen TRT prostate cancer warnings
Experts caution the move amounts to a “huge, unregulated, natural experiment”

In a video captioned “The High-T Department of War” and posted on X, Secretary of Defense Pete Hegseth announced that he was authorizing a screening program for troops to ensure “you have the right testosterone levels to operate at your absolute best.”
By Claire Marie Porter
Drugs & Targets

FDA grants priority review for Talzenna + Xtandi combo in earlier prostate cancer

FDA accepted for Priority Review a supplemental New Drug Application for Talzenna (talazoparib), an oral poly ADP-ribose polymerase inhibitor, in combination with Xtandi (enzalutamide), an androgen receptor pathway inhibitor, in men with homologous recombination repair gene-altered metastatic castration-sensitive prostate cancer, also known as metastatic hormone-sensitive prostate cancer. 
Byline
Mikkael A. Sekeres, MD, MS
Chief, Division of Hematology, Professor of medicine, Sylvester Comprehensive Cancer Center, University of Miami; Author, “Drugs and the FDA: Safety, Efficacy, and the Public’s Trust”
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account